Effect of retatrutide on kidney parameters in people with type 2 diabetes and/or obesity: a post-hoc analysis of two phase 2 trials

被引：0
|
作者：
Heerspink, H. [1 ]
Lu, Z. [2 ]
Du, Y. [2 ]
Duffin, K. [2 ]
Coskun, T. [2 ]
Haupt, A. [2 ]
Hartman, M. L. [2 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[2] Eli Lilly & Co, Indianapolis, IN USA
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
743
引用
收藏
页码：S356 / S356
页数：1
相关论文
共 50 条
  • [31] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Hiren Patel
    Kashif Munir
    Sindee Sutherland
    Chrisanthi A. Karanikas
    Manige Konig
    Diabetes Therapy, 2019, 10 : 2321 - 2330
  • [32] Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
    Patel, Hiren
    Munir, Kashif
    Sutherland, Sindee
    Karanikas, Chrisanthi A.
    Konig, Manige
    DIABETES THERAPY, 2019, 10 (06) : 2321 - 2330
  • [33] Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis
    Araki, Eiichi
    Harashima, Shinichi
    Nishida, Tomoyuki
    Nakamura, Jiro
    JOURNAL OF DIABETES INVESTIGATION, 2022, : 1971 - 1980
  • [34] Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
    Schechter, Meir
    Wiviott, Stephen
    Raz, Itamar
    Goodrich, Erica L.
    Rozenberg, Aliza
    Yanuv, Ilan
    Murphy, Sabina A.
    Zelniker, Thomas A.
    Fredriksson, Martin
    Johansson, Peter A.
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Cahn, Avivit
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Mosenzon, Ofri
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (04): : 233 - 241
  • [35] BARICITINIB EFFICACY IN MODERATE RHEUMATOID ARTHRITIS - A POST-HOC ANALYSIS FROM TWO PHASE III TRIALS
    Kirkham, Bruce W.
    Nikiphorou, Elena
    Edwards, Christopher J.
    Sheesh, Mohamed
    Haladyj, Ewa
    Gerwien, Jens
    Zaremba-Pechmann, Liliana
    Taylor, Peter C.
    RHEUMATOLOGY, 2023, 62
  • [36] Effect of tirzepatide in GADA-positive individuals with type 2 diabetes: a post hoc analysis of the SURPASS 2-5 trials
    Buzzetti, R.
    Peters, A. L.
    Lee, C. J.
    Pavo, I.
    Liu, M.
    Paik, J. S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S312 - S312
  • [37] Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
    Wang, Jingyu
    Yang, Juhong
    Jiang, Wenhui
    Liu, Wenyan
    Shen, Zewei
    Gao, Zhongai
    Chang, Baocheng
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5157 - 5166
  • [38] Smoking and prevalence of nocturia in Japanese patients with type 2 diabetes mellitus: a post-hoc analysis of The Dogo Study
    Furukawa, Shinya
    Sakai, Takenori
    Niiya, Tetsuji
    Miyaoka, Hiroaki
    Miyake, Teruki
    Yamamoto, Shin
    Kanzaki, Sayaka
    Maruyama, Koutatsu
    Tanaka, Keiko
    Ueda, Teruhisa
    Senba, Hidenori
    Torisu, Masamoto
    Minami, Hisaka
    Onji, Morikazu
    Tanigawa, Takeshi
    Matsuura, Bunzo
    Hiasa, Yoichi
    Miyake, Yoshihiro
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 (05) : 1336 - 1341
  • [39] BMI shift and associated cardiometabolic risk factors in people with type 2 diabetes and obesity and/or overweight: a post hoc analysis from SURMOUNT-2
    Sattar, N.
    Lee, C. J.
    Wang, H.
    Grant, G.
    Zhang, X. M.
    Plat, A.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [40] Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials
    Mann, Johannes F. E.
    Hansen, Thomas
    Idorn, Thomas
    Leiter, Lawrence A.
    Marso, Steven P.
    Rossing, Peter
    Seufert, Jochen
    Tadayon, Sayeh
    Vilsboll, Tina
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11): : 880 - 893
12345